Status:
UNKNOWN
Study on the Population Pharmacokinetics of Levetiracetam in Epileptic Patients With Diabetic Kidney Disease
Lead Sponsor:
The Second Hospital of Shandong University
Conditions:
Epilepsy
Diabetic Nephropathy
Eligibility:
All Genders
18-90 years
Brief Summary
The individualized drug delivery system of levetiracetam based on population pharmacokinetics and quantitative pharmacology model in patients with epilepsy complicated by diabetic kidney disease was e...
Detailed Description
A quantitative pharmacological model for the development of levetiracetam in epileptic patients with diabetic nephropathy is proposed. First, a model based active levetiracetam based individualized in...
Eligibility Criteria
Inclusion
- \- Patients with seizures and diabetic nephropathy who were treated with levetiracetam.
Exclusion
- patients who rejected
Key Trial Info
Start Date :
April 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05330390
Start Date
April 4 2022
End Date
December 31 2023
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Hospital of Shandong University
Jinan, Shandong, China, 250033